Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy

dc.contributor.authorÁlvarez Prats, Alejandro
dc.contributor.authorHernández Perera, Octavio
dc.contributor.authorDíaz Herrera, Pilar
dc.contributor.authorUcero Herrería, Álvaro Conrado
dc.contributor.authorAnabitarte Prieto, Aránzazu
dc.contributor.authorLosada Cabrera, Antonio
dc.contributor.authorOrtiz, Alberto
dc.contributor.authorRodríguez Pérez, José C.
dc.date.accessioned2025-01-29T07:39:00Z
dc.date.available2025-01-29T07:39:00Z
dc.date.issued2012-02-01
dc.description.abstractBackground Angiotensin receptor 1 blockers (ARB) are standard nephroprotective drugs in chronic kidney disease. There is less evidence for a nephroprotective effect of HMG-CoA reductase inhibitors (statins) and much less is known about potential benefits of combination therapy. We evaluated the therapeutic potential of a statin alone or in combination with an ARB in experimental chronic kidney disease. Methods Subtotally nephrectomized (5/6 Nx) rats were treated early with vehicle, losartan, cerivastatin or losartan/cerivastatin. Expression of messenger RNA (mRNA) was assessed by real-time reverse transcription–polymerase chain reaction. Tissue proteins were localized by immunohistochemistry. Nuclear factor-κB (NF-κB) activation was measured in whole kidneys. Results In contrast to the sham group, at 6 weeks, vehicle-treated 5/6 Nx rats displayed renal lesions, albuminuria and increased blood pressure, serum creatinine and total kidney NF-κB p65 DNA-binding activity and preproendothelin-1, fibronectin and type I and III collagen mRNA. NF-κB activation correlated with albuminuria and histological renal injury. Losartan or combination therapy preserved renal function, abrogated albuminuria and improved glomerular and interstitial histology. Cerivastatin alone preserved renal function and improved interstitial injury but did not influence albuminuria, glomerular histology or NF-κB activation. Losartan/cerivastatin normalized kidney NF-κB activation and extracellular matrix mRNA expression pattern. The effect of losartan alone on these parameters was less intense. All treatments decreased preproendothelin-1 mRNA and preserved interstitial capillaries. Conclusions In a chronic kidney disease model, early treatment with either an ARB or a statin preserved renal function although the mechanisms differed. Combination therapy with an ARB and a statin did not confer clear-cut advantages on biochemical and histological parameters over ARB alone, although it further improved the kidney NF-κB and gene expression profile.
dc.description.departmentDepto. de Fisiología
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipInstituto de Salud Carlos III (España)
dc.description.sponsorshipComunidad Autónoma de Madrid
dc.description.statuspub
dc.identifier.citationAlejandro Álvarez-Prats, Octavio Hernández-Perera, Pilar Díaz-Herrera, Álvaro C. Ucero, Aránzazu Anabitarte-Prieto, Antonio Losada-Cabrera, Alberto Ortiz, José C. Rodríguez-Pérez, Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy, Nephrology Dialysis Transplantation, Volume 27, Issue 7, July 2012, Pages 2720–2733, https://doi.org/10.1093/ndt/gfr671
dc.identifier.doi10.1093/ndt/gfr671
dc.identifier.essn1460-2385
dc.identifier.issn0931-0509
dc.identifier.officialurlhttps://doi.org/10.1093/ndt/gfr671
dc.identifier.pmid22302208
dc.identifier.relatedurlhttps://academic.oup.com/ndt/article/27/7/2720/1844452?login=true
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/22302208/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/116735
dc.issue.number7
dc.journal.titleNephrology Dialysis Transplantation
dc.language.isoeng
dc.page.final2733
dc.page.initial2720
dc.publisherOxford Academics
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/FIS01/1018
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/FISPS09/00447
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII-RETIC/REDinREN/RD06/0003
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII-RETIC/REDinREN/ RD06/0004
dc.relation.projectIDinfo:eu-repo/grantAgreement/CAM/FRACM/S-BIO0283/2006
dc.rights.accessRightsrestricted access
dc.subject.cdu612
dc.subject.keywordInflammation
dc.subject.keywordAngiotensin
dc.subject.keywordKidney injury
dc.subject.ucmCiencias Biomédicas
dc.subject.ucmMedicina
dc.subject.ucmFisiología
dc.subject.unesco24 Ciencias de la Vida
dc.subject.unesco32 Ciencias Médicas
dc.titleCombination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number27
dspace.entity.typePublication
relation.isAuthorOfPublication271766ba-4fd6-4ae1-9268-8f8641f448d3
relation.isAuthorOfPublication.latestForDiscovery271766ba-4fd6-4ae1-9268-8f8641f448d3

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy_NDT_2012.pdf
Size:
905.87 KB
Format:
Adobe Portable Document Format

Collections